Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Completed 31Unknown 3Terminated 3

Sponsor Class

NIH 3

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other solid neoplasm 1Breast 1

Conditions

Unspecified Childhood Solid Tumor, Protocol Specific 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 283Drug Therapy 243apatinib 242Bevacizumab 229camrelizumab 214Etoposide 200Irinotecan 176Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Interventional × Immunologic Techniques × Clear all
NCT00436709 2014-01-06

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

National Cancer Institute (NCI)

Phase NA Unknown
75 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00436761 2013-12-18

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

National Cancer Institute (NCI)

Phase 1 Unknown
20 enrolled
Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

NCT00742404 2013-12-18

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Unknown
35 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡